Business & Finance

Corautus Genetics reports second quarter financial results

Published in Medical Letter on the CDC and FDA, September 10th, 2006

Corautus Genetics Inc. (VEGF), a clinical stage biopharmaceutical company, reported financial results for the three and six months ended June 30, 2006.

Corautus had cash, cash equivalents and short-term investments of $22,813,000 as of June 30, 2006. Corautus expects that its existing capital resources will be sufficient to fund its current and planned operations through the end of the third quarter of 2007.

Revenues were $21,000 for the three months ended June 30, 2006 and 2005 and $42,000 for the six months ended June 30, 2006 and 2005, reflecting the amortization of a payment received from the sublicense of certain patents to Boston Scientific...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-09-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry